Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chiron Taps GSK International Pharma Head Pien For CEO Post

Executive Summary

GlaxoSmithKline International Pharmaceuticals President Howard Pien will join Chiron as CEO and president by the end of April

You may also be interested in...



Chiron Lands Lance As CEO; Biotech Firm Seeking To Sharpen Image

Chiron is turning to former Glaxo Chief Operating Officer Sean Lance to help sharpen its image with investors - and to manage a transition in its relationship with Novartis.

Glaxo U.S. COO search is priority for CEO Ingram following his elevation to CEO of global business.

GLAXO U.S. CHIEF OPERATING OFFICER SEARCH IS PRIORITY FOR CEO INGRAM following his elevation to CEO of Glaxo Wellcome, plc. Robert Ingram will retain his position as head of the U.S. operating division of Glaxo (Glaxo Wellcome, Inc.) but will name a COO as soon as possible, the company said Oct. 28. The lack of an immediate successor to handle day-to-day U.S. operations highlights the suddenness of Glaxo's announcement of Ingram's promotion. Another indication of the suddenness of the change is that Ingram made a scheduled Oct. 27 presentation to the Oppenheimer investment conference, one day before the promotion was announced.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS041468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel